ORAL DOSAGE OF ANTI-AIDS AGENTS

该资源功能的目标是开发和生产 药学上可接受的剂型或前景看好的新制剂 抗艾滋病活动。一些由药物遴选委员会在 NIH将被指派开发和制造非口腔产品。 最初，预计第一阶段和第二阶段的批次规模较小 审判。然而，升级到大批量的III/IV阶段试验 并预计C组分布。据估计，这一点 必须准备生产数百万个口服剂量单位的项目 每年。

The objective of this resource function is to develop and produce pharmaceutically acceptable dosage forms or promising new agents with anti-AIDS activity. Some agents selected by a Drug Selection Committee at NIH will be assigned for development and manufacture asoral products. Initially, the batch sizes are expected to be small for Phase I and II trials. However, escalation to large batch sizes for Phase III/IV trials and Group C distribution is anticipated. It is estimated that this project must be prepared to produce several million oral dosage units each year.